Controlling blood glucose early in the course of type 1 diabetes yields huge dividends, preserving kidney function for decades. The new finding from a study funded by the National Institutes of Health was published online in the New England Journal of Medicine Nov. 12 to coincide with presentation at a scientific meeting.
Compared to conventional therapy, near-normal control of blood glucose beginning soon after diagnosis of type 1 diabetes and continuing an average six and a half years reduced by half the long-term risk of developing kidney disease, according to the Diabetes Control and Complications Trial (DCCT) and Epidemiology of Diabetes Interventions and Complications (EDIC) Research Group. The risk of kidney failure was also halved, but the difference was not statistically significant, perhaps due to the relatively small total number of patients who reached that stage of the disease.
Participants entered the DCCT on average six years after onset of diabetes when complications of diabetes were absent or very mild. Half aimed for near-normal glucose control (intensive therapy) and the others received what was then standard glucose control. After an average 22-year follow-up, 24 in the intensive group developed significantly reduced kidney function and 8 progressed to kidney failure requiring dialysis or transplantation. On conventional therapy, 46 developed kidney disease, with kidney failure in 16.
The landmark DCCT demonstrated that intensive control reduced early signs of eye, kidney and nerve damage and is the basis for current guidelines for diabetes therapy. However, the initial kidney findings were based on reductions in urine protein, a sign of kidney damage but not a measure of kidney function. Preventing a loss of kidney function and reducing kidney failure had not been proven.
Since the DCCT ended in 1993, all participants have tried to maintain excellent diabetes control and have achieved similar glucose levels. The new finding emphasizes the importance of good control of type 1 diabetes soon after diagnosis.
"Achieving near-normal glucose levels in type 1 diabetes can be challenging. But our study provides strong evidence that reinforces the benefits of reaching the goal as early as possible to slow or prevent kidney disease and other complications," said first author Ian H. de Boer, M.D., a kidney specialist at the University of Washington, Seattle. He is scheduled to present the findings Nov. 12, 2011, at the American Society of Nephrology's annual meeting in Philadelphia.
The DCCT, conducted from 1983 to 1993 in 1,441 people with type 1 diabetes, found that intensive glucose control was superior to conventional control in delaying or preventing complications overall. EDIC continues to follow 1,375 DCCT participants to determine the long-term effects of the therapies beyond the initial treatment period. Other reports have bolstered support for intensive treatment to reduce the risk of heart disease, stroke and eye and nerve damage associated with diabetes.
"The DCCT and EDIC studies illustrate the value of long-term studies. The full benefit of treatment may not be seen for decades, especially for complications of diabetes, such as kidney disease, which can progress slowly but have devastating consequences," said Griffin P. Rodgers, M.D., director of the NIH's National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), which oversaw the research. "Not only has NIH-sponsored research shown the benefits of early glucose control, it has provided new tools to help people with type 1 diabetes achieve that control and live longer and healthier lives."
The DCCT compared intensive to conventional control of blood glucose in people with type 1 diabetes. At the time, conventional treatment was one or two insulin injections a day with daily urine or blood glucose testing. Participants randomly assigned to intensive treatment were asked to keep glucose levels as near normal as possible. That meant trying to keep hemoglobin A1c (A1C) readings at 6 percent or less with at least three insulin injections a day or an insulin pump, guided by frequent self-monitoring of blood glucose. (A1C reflects average blood glucose over the previous two to three months.)
Nearly 26 million Americans have diabetes. In adults, type 1 diabetes accounts for 5 to 10 percent of all diagnosed cases of the disease. Formerly called juvenile-onset or insulin-dependent diabetes, type 1 diabetes develops when the body's immune system destroys pancreatic beta cells, the only cells in the body that make the hormone insulin that regulates blood glucose. Type 1 diabetes usually arises in children and young adults but can occur at any age. Management involves keeping blood glucose levels as close to normal as possible with three or more insulin injections a day or treatment with an insulin pump, careful monitoring of glucose, and close attention to diet and exercise.
Type 2 diabetes, or adult-onset diabetes, accounts for about 90 to 95 percent of all diabetes diagnosed in adults. It usually begins as insulin resistance, a disorder in which the cells do not use insulin properly. As the need for insulin rises, the pancreas gradually loses its ability to produce it. Type 2 diabetes is associated with older age, obesity, family history of diabetes, history of gestational diabetes, impaired glucose metabolism, physical inactivity, and race/ethnicity. African-Americans, Hispanic/Latino-Americans, American Indians, and some Asian-Americans and Native Hawaiians or other Pacific Islanders are at particularly high risk for type 2 diabetes and its complications.
Chronic kidney disease can lead to kidney failure, also called end-stage renal disease, requiring dialysis or a kidney transplant for survival. Chronic kidney disease affects more than 10 percent of Americans over age 20 and 35 percent of those over age 20 with diabetes. People with diabetes and chronic kidney disease account for 26.1 percent, or $18 billion, of Medicare costs for diabetes. Diabetes is the leading cause of kidney failure, accounting for nearly 38 percent (215,000) of Americans on dialysis or living with a kidney transplant. Each year 110,000 patients in the United States start treatment for kidney failure. These lifesaving treatments cost $42.5 billion annually.
The DCCT is registered as NCT00360815, and EDIC is registered as NCT00360893 in clinicaltrials.gov. NIDDK and other NIH components supporting DCCT/EDIC are the National Eye Institute, the National Institute of Neurological Disorders and Stroke and the National Center for Research Resources. Genentech contributed to the DCCT/EDIC through a Cooperative Research and Development Agreement with the NIDDK. Lifescan, Roche, Aventis, Eli Lilly, Omnipod, Can-Am, B-D, Animas, Medtronic, Medtronic Minimed, Bayer and Omron contributed free or discounted supplies to the DCCT/EDIC.
The NIDDK, a component of the NIH, conducts and supports research on diabetes and other endocrine and metabolic diseases; digestive diseases, nutrition and obesity; and kidney, urologic and hematologic diseases. Spanning the full spectrum of medicine and afflicting people of all ages and ethnic groups, these diseases encompass some of the most common, severe and disabling conditions affecting Americans. For more information about the NIDDK and its programs, see http://www.niddk.nih.gov. Education programs for diabetes and kidney disease offer information and resources for patients and health professionals.
About the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit http://www.nih.gov.
Mary M. Harris | EurekAlert!
Using fragment-based approaches to discover new antibiotics
21.06.2018 | SLAS (Society for Laboratory Automation and Screening)
Scientists learn more about how gene linked to autism affects brain
19.06.2018 | Cincinnati Children's Hospital Medical Center
In a recent publication in the renowned journal Optica, scientists of Leibniz-Institute of Photonic Technology (Leibniz IPHT) in Jena showed that they can accurately control the optical properties of liquid-core fiber lasers and therefore their spectral band width by temperature and pressure tuning.
Already last year, the researchers provided experimental proof of a new dynamic of hybrid solitons– temporally and spectrally stationary light waves resulting...
Scientists from the University of Freiburg and the University of Basel identified a master regulator for bone regeneration. Prasad Shastri, Professor of...
Moving into its fourth decade, AchemAsia is setting out for new horizons: The International Expo and Innovation Forum for Sustainable Chemical Production will take place from 21-23 May 2019 in Shanghai, China. With an updated event profile, the eleventh edition focusses on topics that are especially relevant for the Chinese process industry, putting a strong emphasis on sustainability and innovation.
Founded in 1989 as a spin-off of ACHEMA to cater to the needs of China’s then developing industry, AchemAsia has since grown into a platform where the latest...
The BMBF-funded OWICELLS project was successfully completed with a final presentation at the BMW plant in Munich. The presentation demonstrated a Li-Fi communication with a mobile robot, while the robot carried out usual production processes (welding, moving and testing parts) in a 5x5m² production cell. The robust, optical wireless transmission is based on spatial diversity; in other words, data is sent and received simultaneously by several LEDs and several photodiodes. The system can transmit data at more than 100 Mbit/s and five milliseconds latency.
Modern production technologies in the automobile industry must become more flexible in order to fulfil individual customer requirements.
An international team of scientists has discovered a new way to transfer image information through multimodal fibers with almost no distortion - even if the fiber is bent. The results of the study, to which scientist from the Leibniz-Institute of Photonic Technology Jena (Leibniz IPHT) contributed, were published on 6thJune in the highly-cited journal Physical Review Letters.
Endoscopes allow doctors to see into a patient’s body like through a keyhole. Typically, the images are transmitted via a bundle of several hundreds of optical...
13.06.2018 | Event News
08.06.2018 | Event News
05.06.2018 | Event News
21.06.2018 | Earth Sciences
21.06.2018 | Life Sciences
21.06.2018 | Earth Sciences